Comment on “Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)”

Ítems similars

• Neoadjuvant Chemoradiation with IMRT in Resectable and Borderline Resectable Pancreatic Cancer
  per: Kharofa, Jordan, et al.
  Publicat: (2014)
• Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
  per: Hu, Qiancheng, et al.
  Publicat: (2019)
• Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
  per: Blazer, Marlo, et al.
  Publicat: (2014)
• Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
  per: Katherine V. Trinh, et al.
  Publicat: (2020-09-01)
• Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
  per: Trinh, Katherine V., et al.
  Publicat: (2020)